Last reviewed · How we verify

Innovaderm Research Inc. — Portfolio Competitive Intelligence Brief

Innovaderm Research Inc. pipeline: 1 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Eucerin Eucerin marketed Other
Adalimumab Every Week Adalimumab Every Week phase 3 TNF-alpha inhibitor TNF-alpha (Tumor Necrosis Factor-alpha) Immunology
Adalimumab every other week Adalimumab every other week phase 3 TNF-α inhibitor TNF-α (tumor necrosis factor-alpha) Immunology
Placebo / Xeomin Placebo / Xeomin phase 3 Botulinum toxin type A SNARE complex (synaptosome-associated protein) Neurology / Aesthetics

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Alvotech Swiss AG · 2 shared drug classes
  2. Abbott · 2 shared drug classes
  3. AbbVie (prior sponsor, Abbott) · 1 shared drug class
  4. Altuğ Güner · 1 shared drug class
  5. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  6. Asan Medical Center · 1 shared drug class
  7. ATGC Co., Ltd. · 1 shared drug class
  8. ASIS Corporation · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Innovaderm Research Inc.:

Cite this brief

Drug Landscape (2026). Innovaderm Research Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/innovaderm-research-inc. Accessed 2026-05-16.

Related